Long-Term Outcome of Soft Tissue Sarcomas Treated With Mesna-Doxorubicin-Ifosfamid-Dacarbazine Regimen (Maid): A Retrospective Study From a Singe Institution

Aim:fSoft tissue sarcomas (STSs) account for 1% of cancers in the adult population. The treatment of choice is surgery but chemotherapy and/or radiotherapy are frequently used due to aggressive cancer behavior or incomplete surgery. Doxorubicin-based regimens are the most frequently used chemotherapy combinations but real-life data about the efficacy and safety of these agents in our country is limited. We aimed to present clinicodemographic and prognostic features of STS cases treated with mesna, doxorubicin, ifosfamide, dacarbazine (MAID regimen).Materials and Methods:A total of forty-five STS cases who were diagnosed between 2007-2016 and treated with the MAID regimen as the initial therapy in Cukurova University were analyzed retrospectively. Associations between clinicodemographic parameters with overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves and with the logrank test. Univariate-multivariate analyses were used to assess the prognostic values of parameters for OS-PFS.Results:The median age of the patients was 49 and the most common STS subtypes were undifferentiated pleomorphic carcinoma (37.8%) followed by liposarcoma (17.8%) and leiomyosarcoma (13.3%). According to the AJCC TNM stages, 15.6% stage 1-2, 53.3% stage 3, and 31.1% stage 4 disease. The median PFS/OS were 17/39 months, respectively. The 5-year PFS/OS rates were 14%/32.5%, respectively. In univariate analyses, mitosis, necrosis, stage, and surgery were both prognostic for PFS-OS. However, in multivariate analysis, only stage was an independent prognostic factor both for PFS-OS.Conclusion:Stage was the only independent prognostic factor for both PFS-OS in patients with STS who received the MAID chemotherapy as initial therapy

DDR1 may be a good biomarker for brain tumors.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2019 -- Chicago, ILWOS: 000487345800374…Amer Soc Clin Onco

The prognostic analysis of the some clinicopathological parameters and gene protein expressions in malignant mesothelioma

WOS: 000493372200002PubMed ID: 31709947Introduction: Mesothelioma is an aggressive tumour that originates in serous surfaces. The primary end point of this study was to invastigate the relationship of progression free survival (PFS) and overall survival (OS) with the c-Met, EGFR, PTEN, PDGFR-alpha, PI3K/AKT and mTOR expression levels in the tumour tissue of pleural and peritoneal mesothelioma cases. Materials and Methods: The study included 53 patients diagnosed with mesothelioma between 2005 and 2016. The cases were separated into 2 groups as pleural and peritoneal. The effects on OS and PFS were examined of the c-Met, EGFR, PTEN, PDGFR-alpha, PI3K/AKT and mTOR expression levels and also clinicopathological parameters and the treatments given. In the statistical analysis of the data obtained, IBM SPSS vn 20.0 software was used. Results: Of the 53 patients included in the study, 39 (73.6%) were diagnosed with pleural mesothelioma and 14 (26.4%) with peritoneal mesothelioma. According to the c-Met and mTOR expression, OS and PFS of the peritoneal cases with high expression (2+, 3+) was seen to be significantly better than that of the peritoneal cases with low expression (0, 1+) (p < 0.05). According to the PDGFR expression, OS and PFS of the pleural cases with low expression (0, 1+) was seen to be significantly better than that of the pleural cases with high expression (2+, 3+) (p < 0.05). Conclusion: The examination of c-MET, PDGFR-alpha and m-TOR expression in the in the tumor tissue of mesothelioma cases may be important in determining prognosis

Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2019 -- Chicago, ILWOS: 000487345801503…Amer Soc Clin Onco

Merkel cell carcinoma in Turkey: A multicentric study.

WOS: 000442916006728

Assessment of potential predictive value o f peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study

WOS: 000465259600002PubMed ID: 31114378Purpose: The aim of this study was to evaluate the prognostic and predictive value o f neutrophilto-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (DNLR), lymphocyte-tomonocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) in soft tissue sarcoma (STS) cases treated with pazopanib. Materials and methods: The study population included 26 STS cases treated with pazopanib for at least 3 months. NLR, DNLR, LMR, and PLR were evaluated at baseline, and at third month of therapy and also compared with response to pazopanib. Median measurements were taken as cutoff for NLR (4.8), DNLR (3.1), LMR (3.6), and PLR (195). The associations between these cutoff values and survival times (progression-free survival [PFS] and overall survival [OS]) were assessed by Kaplan-Meier curves and Cox proportional models. Results: Patients with low pretreatment NLR and DNLR had longer OS (P=0.022, P=0.018), but low PLR was found to be associated only with longer OS. Additionally, decrease in NLR and DNLR after 3 months of therapy as compared with pretreatment measurements was found to be associated with an advantage for OS (P=0.021, P=0.010, respectively) and PFS (P=0.005, P=0.001, respectively). Response to pazopanib; changes in NLR, DNLR, LMR, and PLR; and >3 metastatic sites were found to be independent risk factors in univariate analysis, but NLR was the only independent risk factor in multivariate analysis. Conclusion: Low pretreatment and decrease in NLR and DNLR values, and regression/stable disease after 3 months of pazopanib are predictive factors for longer OS and PFS

Pulmonary MALT lymphoma with underlying interstitial lung disease: A case report and rewiev of the literature

Marginal zone lymphoma (MZL) is low grade lymphoma and accounts about 5% of all lymphomas and 5–10% of MZLs are localized in the lung. Interstitial Lung Disease (ILD) is a group of systemic diseases characterized by diffuse inflammation in lung and there is a long list for differential diagnosis. Here we represent a 53 years old man who had been followed as ILD by the department of chest diseases for 1,5 years. Biopsy taken by wedge resection was reported as MZL. Keywords: Non-Hodgkin lymphoma, Interstitial lung disease, MALT lymphom

sj-docx-1-opp-10.1177_10781552231171322 - Supplemental material for Brigatinib-associated autoimmune hepatitis: A case report

Supplemental material, sj-docx-1-opp-10.1177_10781552231171322 for Brigatinib-associated autoimmune hepatitis: A case report by Mahmut Buyuksimsek, Ali Ogul, Abdullah Evren Yetisir, Berna Bozkurt Duman, Mert Tohumcuoglu, Timucin Cil, Tolga Koseci, Mehmet Mutlu Kidi and Hilmi Erdem Sumbul in Journal of Oncology Pharmacy Practice</p

Multisystemic Long-Term Sequelae of Covid-19: A Review Based on the Current Literature Over a Year of Pandemic Experience

On January 7, 2020, it was announced that the Chinese Government isolated a new variant of Coronavirus (SARS CoV-2). Officials reported that populations were not equally affected in terms of the number of cases, severe illness, and death. As of 28 December 2020, 81,000,000 cases have been confirmed globally, and approximately 1,770,000 total deaths have been reported for COVID-19. Besides difficulties of COVID-19 management in the acute stage, long-term consequences of the infection could cause widespread public health problems across the World. This review article aims to examine current literature regarding COVID-19, identify post-illness sequelae, detect patients at risk for sequelae, and provide guidance to management strategies. In the report, long-term pulmonary sequels and systemic problems including cardiovascular, neurological, psychiatric, endocrinologic, nephrological, hematologic, gastrointestinal, dermatologic, etc. of COVID-19 are discussed in accordance with recent scientific publications